摘要
目的探讨舒洛地特对早期糖尿病肾病的治疗作用。方法选取56例2型糖尿病并发糖尿病肾病的患者,尿白蛋白排泌率(20～200)μg/min,予舒落地特针每日2mL,肌注,共1个月,观察治疗前后尿白蛋白排泌率(UAER),凝血纤溶指标包括组织型纤溶酶原激活剂(t-PA),纤溶酶原激活抑制物-1(PAI-1),纤维蛋白原(Fbg)、PT、TT、APTT的改变及血脂的变化。结果治疗1个月后患者尿白蛋白排泌率(UAER)明显低于治疗前(P<0.01),t-PA较治疗前升高、PAI-1、Fbg均较治疗前降低(P<0.05),PT、TT、APTT较治疗前延长(P<0.05),血脂治疗前后变化无统计学意义。结论舒洛地特可通过多种机制减少尿蛋白,治疗糖尿病肾病,无明显出血的不良反应。
Objective To observe the effect of sulodexide on early diabetic nephropathy. Methods The treatment research was made within 56 patients of type 2 diabetic nephropathy.Their urine albumin excretion rate （ UAER ） was （ 20 ~ 200 ） ~L g/min. The patients were given 2mL sulodexide, im qd, for one month.The test index includes： UAER （ be tested before and after the treatment ）, tissue- type plasminogen activator （ t-PA ）, plasminogen activator inhibitor （ PAI-1 ）, fibrinogen （ Fbg ）, PT, TT, APTT, blood fat. Results The results showed that the UAER decreased after one month treatment with sulodexide （P ~ 0.01 ）. After the treatment, t-PA was obviously increased （P ~ 0.05 ）, indexes of PAI-1, Fib clearly reduced （P 〈 0.05 ）, PT, TT, APTT obviously delayed （P 〈 0.05 ）, but index of blood fat had not distinct changed. Conclusion Sulodexide can reduce the UAER of type 2 early diabetic nephropathy through many mechanisms.
出处
《中国现代医生》
2011年第25期153-154,共2页
China Modern Doctor
